vs
Orthofix Medical Inc.（OFIX）与联合果品公司（UFCS）财务数据对比。点击上方公司名可切换其他公司
联合果品公司的季度营收约是Orthofix Medical Inc.的1.7倍（$365.8M vs $219.9M），联合果品公司同比增速更快（9.8% vs 2.0%），过去两年联合果品公司的营收复合增速更高（11.2% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
联合果品公司是一家美国跨国企业，主营在拉丁美洲种植园种植的热带水果贸易，产品销往美国与欧洲。公司1899年由波士顿果品公司与迈纳·C·基思的香蕉贸易企业合并成立，在20世纪上半叶发展蓬勃，掌控了中美洲、哥伦比亚加勒比海岸及西印度群岛的大片领地与运输网络。
OFIX vs UFCS — 直观对比
营收规模更大
UFCS
是对方的1.7倍
$219.9M
营收增速更快
UFCS
高出7.8%
2.0%
两年增速更快
UFCS
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $365.8M |
| 净利润 | $-2.2M | — |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | 13.2% |
| 净利率 | -1.0% | — |
| 营收同比 | 2.0% | 9.8% |
| 净利润同比 | 92.4% | — |
| 每股收益（稀释后） | $-0.05 | $1.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXUFCS
| Q4 25 | $219.9M | $365.8M | ||
| Q3 25 | $205.6M | $354.0M | ||
| Q2 25 | $203.1M | $335.5M | ||
| Q1 25 | $193.6M | $331.1M | ||
| Q4 24 | $215.7M | $333.2M | ||
| Q3 24 | $196.6M | $323.0M | ||
| Q2 24 | $198.6M | $301.2M | ||
| Q1 24 | $188.6M | $296.0M |
净利润OFIXUFCS
| Q4 25 | $-2.2M | — | ||
| Q3 25 | $-22.8M | $39.2M | ||
| Q2 25 | $-14.1M | $22.9M | ||
| Q1 25 | $-53.1M | $17.7M | ||
| Q4 24 | $-29.1M | — | ||
| Q3 24 | $-27.4M | $19.7M | ||
| Q2 24 | $-33.4M | $-2.7M | ||
| Q1 24 | $-36.0M | $13.5M |
毛利率OFIXUFCS
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — | ||
| Q1 24 | 67.5% | — |
营业利润率OFIXUFCS
| Q4 25 | 0.2% | 13.2% | ||
| Q3 25 | -8.3% | 13.7% | ||
| Q2 25 | -7.9% | 8.7% | ||
| Q1 25 | -25.2% | 6.6% | ||
| Q4 24 | -5.3% | 11.9% | ||
| Q3 24 | -9.6% | 7.7% | ||
| Q2 24 | -12.5% | -1.3% | ||
| Q1 24 | -15.6% | 5.5% |
净利率OFIXUFCS
| Q4 25 | -1.0% | — | ||
| Q3 25 | -11.1% | 11.1% | ||
| Q2 25 | -6.9% | 6.8% | ||
| Q1 25 | -27.4% | 5.3% | ||
| Q4 24 | -13.5% | — | ||
| Q3 24 | -13.9% | 6.1% | ||
| Q2 24 | -16.8% | -0.9% | ||
| Q1 24 | -19.1% | 4.6% |
每股收益（稀释后）OFIXUFCS
| Q4 25 | $-0.05 | $1.45 | ||
| Q3 25 | $-0.57 | $1.49 | ||
| Q2 25 | $-0.36 | $0.87 | ||
| Q1 25 | $-1.35 | $0.67 | ||
| Q4 24 | $-0.76 | $1.22 | ||
| Q3 24 | $-0.71 | $0.76 | ||
| Q2 24 | $-0.88 | $-0.11 | ||
| Q1 24 | $-0.95 | $0.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $156.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $941.2M |
| 总资产 | $850.6M | $3.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXUFCS
| Q4 25 | $82.0M | $156.3M | ||
| Q3 25 | $62.9M | $233.7M | ||
| Q2 25 | $65.6M | $202.1M | ||
| Q1 25 | $58.0M | $183.7M | ||
| Q4 24 | $83.2M | $200.9M | ||
| Q3 24 | $30.1M | $197.4M | ||
| Q2 24 | $26.4M | $153.4M | ||
| Q1 24 | $27.0M | $217.8M |
总债务OFIXUFCS
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXUFCS
| Q4 25 | $450.0M | $941.2M | ||
| Q3 25 | $442.5M | $898.7M | ||
| Q2 25 | $458.3M | $845.7M | ||
| Q1 25 | $458.3M | $817.7M | ||
| Q4 24 | $503.1M | $781.5M | ||
| Q3 24 | $525.9M | $785.8M | ||
| Q2 24 | $546.0M | $726.6M | ||
| Q1 24 | $570.3M | $736.8M |
总资产OFIXUFCS
| Q4 25 | $850.6M | $3.8B | ||
| Q3 25 | $832.6M | $3.8B | ||
| Q2 25 | $837.2M | $3.7B | ||
| Q1 25 | $823.1M | $3.5B | ||
| Q4 24 | $893.3M | $3.5B | ||
| Q3 24 | $867.9M | $3.5B | ||
| Q2 24 | $882.0M | $3.4B | ||
| Q1 24 | $906.0M | $3.2B |
负债/权益比OFIXUFCS
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $269.7M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | — |
| 自由现金流率自由现金流/营收 | 7.6% | — |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXUFCS
| Q4 25 | $27.7M | $269.7M | ||
| Q3 25 | $12.4M | $60.8M | ||
| Q2 25 | $11.6M | $53.4M | ||
| Q1 25 | $-18.4M | $35.7M | ||
| Q4 24 | $23.7M | $340.3M | ||
| Q3 24 | $11.7M | $56.5M | ||
| Q2 24 | $9.0M | $91.3M | ||
| Q1 24 | $-18.6M | $36.2M |
自由现金流OFIXUFCS
| Q4 25 | $16.8M | — | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $4.5M | — | ||
| Q1 25 | $-25.1M | — | ||
| Q4 24 | $15.2M | — | ||
| Q3 24 | $6.3M | — | ||
| Q2 24 | $-360.0K | — | ||
| Q1 24 | $-29.1M | — |
自由现金流率OFIXUFCS
| Q4 25 | 7.6% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 2.2% | — | ||
| Q1 25 | -13.0% | — | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | -0.2% | — | ||
| Q1 24 | -15.4% | — |
资本支出强度OFIXUFCS
| Q4 25 | 4.9% | — | ||
| Q3 25 | 4.8% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 3.5% | — | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 4.7% | — | ||
| Q1 24 | 5.6% | — |
现金转化率OFIXUFCS
| Q4 25 | — | — | ||
| Q3 25 | — | 1.55× | ||
| Q2 25 | — | 2.33× | ||
| Q1 25 | — | 2.02× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.86× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.68× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
UFCS
暂无分部数据
